Pacamara Coffee (Coffea arabica)

Pacamara coffee is a large-bean Arabica hybrid cultivar (Pacas × Maragogipe) containing caffeine at 1.32–1.42% and notable concentrations of 5-caffeoylquinic acid, a chlorogenic acid subtype with antioxidant properties. No clinical trials specific to Pacamara have been conducted, so its health effects are extrapolated from general Coffea arabica research.

Origin & History

Pacamara is a hybrid cultivar of Coffea arabica, developed in El Salvador from a cross between Pacas (a Bourbon mutation) and Maragogipe varieties by the Salvadoran Institute of Coffee Research. The beans undergo standard coffee processing (wet or dry methods) and contain typical C. arabica compounds including caffeine (~1.4%) and chlorogenic acids.

Historical & Cultural Context

Pacamara is a modern hybrid cultivar from El Salvador with no documented traditional medicinal use. As a recently developed coffee variety focused on agricultural yield and sensory qualities, it lacks the historical therapeutic applications found in some botanical medicines.

Health Benefits

• No specific health benefits demonstrated - No clinical trials on Pacamara coffee were identified in the research
• General C. arabica components present - Contains caffeine (1.32-1.42%) and chlorogenic acids typical of coffee
• Potential antioxidant compounds - Contains 5-caffeoylquinic acid (up to 3.79 g/100g in related varieties)
• Standard coffee bioactives - Shares chemical composition with C. arabica including proteins (13%) and lipids (6-10%)
• No evidence-based claims possible - Absence of human studies prevents specific benefit claims

How It Works

Caffeine in Pacamara coffee acts as a nonselective adenosine receptor antagonist (A1 and A2A receptors), blocking adenosine-mediated inhibition of cAMP production, which promotes alertness and sympathomimetic activity. The primary polyphenol, 5-caffeoylquinic acid (5-CQA), inhibits glucose-6-phosphatase and activates Nrf2/ARE signaling pathways, contributing to antioxidant and potential glycemic-modulating effects. Chlorogenic acids also modulate gut incretin hormone release, potentially affecting postprandial glucose metabolism, though this has not been tested specifically in Pacamara preparations.

Scientific Research

No clinical trials, RCTs, or meta-analyses specific to Pacamara coffee were identified in the research. While general C. arabica studies exist on coffee components (e.g., PMID 35454667 on by-product composition), none directly evaluate Pacamara for biomedical outcomes.

Clinical Summary

No randomized controlled trials or observational studies have been conducted specifically on Pacamara coffee as a distinct cultivar. Available evidence is extrapolated from broader Coffea arabica research, including systematic reviews showing that regular coffee consumption (3–5 cups/day) is associated with reduced type 2 diabetes risk (RR ~0.75) and cardiovascular mortality. Studies on chlorogenic acid extracts from Arabica coffee have used doses of 140–400 mg/day in trials with 20–120 participants, showing modest reductions in blood pressure (2–4 mmHg) and fasting glucose. The evidence base for Pacamara-specific benefits remains absent, and any health claims for this cultivar are speculative pending direct investigation.

Nutritional Profile

Pacamara coffee (Coffea arabica hybrid of Pacas × Maragogipe) shares the core biochemical profile of C. arabica with some varietal distinctions. Caffeine content: 1.32–1.42% dry weight basis (moderate-to-typical arabica range, lower than robusta's ~2.7%). Chlorogenic acids (CGAs): primary bioactive class, dominated by 5-caffeoylquinic acid (5-CQA) at approximately 3.00–3.79 g/100g dry weight in comparable arabica varieties; total CGA content in green arabica beans typically 6–10 g/100g dry weight, reduced to 1–3 g/100g after roasting due to thermal degradation. Trigonelline: ~1.0–1.2 g/100g green bean (precursor to niacin/B3 upon roasting, yielding ~10–40 mg niacin per 100g roasted bean). Lipids: arabica beans contain 15–17% lipid dry weight, comprising predominantly triacylglycerols and diterpenes cafestol and kahweol (~0.2–0.5% of green bean weight), which are largely retained in unfiltered brew. Protein: 10–13% dry weight in green beans, largely denatured during roasting into Maillard reaction products contributing to flavor. Carbohydrates: sucrose 6–9% in green beans (nearly fully degraded during roasting); polysaccharides (galactomannans, arabinogalactans) 50–55% dry weight, partially acting as prebiotic fiber. Minerals per 240ml brewed cup (approximate): magnesium 7–10 mg, potassium 100–115 mg, niacin 0.5–1 mg. Roasting degree significantly impacts final cup bioactive concentrations — light roast preserves higher CGA content; dark roast increases antioxidant melanoidin compounds. Bioavailability: CGAs are 30–60% absorbed in the small intestine; remainder metabolized by colonic microbiota into phenolic acids (ferulic, dihydrocaffeic acids). Pacamara-specific compositional data is limited; values extrapolated from C. arabica cultivar literature.

Preparation & Dosage

No clinically studied dosage ranges for Pacamara coffee have been established. The cultivar contains standard C. arabica levels of caffeine (1.32-1.42%) and chlorogenic acids, but no standardized extracts or therapeutic doses have been researched. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Green tea extract, L-theanine, Rhodiola rosea, Ashwagandha, CoQ10

Safety & Interactions

Pacamara coffee carries the same safety profile as other Coffea arabica preparations; caffeine at typical consumption levels (200–400 mg/day) is generally recognized as safe for healthy adults but may cause insomnia, tachycardia, and anxiety at higher intakes. Caffeine inhibits CYP1A2 metabolism and can interact with medications including ciprofloxacin, fluvoxamine, and clozapine, increasing their plasma concentrations. Pregnant individuals are advised to limit caffeine to under 200 mg/day due to associations with low birth weight and miscarriage risk. Individuals with arrhythmias, severe hypertension, or GERD should exercise caution, and caffeine can potentiate stimulant effects of ephedrine or pseudoephedrine.